NCT00971360

Brief Summary

The aim of this study is whether the proinflammatory cytokine levels in patients with conversion disorder is increased or not changed in the acute phase and subacute - chronic periode, compared with controls.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2009

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

September 2, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 3, 2009

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2010

Completed
Last Updated

October 20, 2010

Status Verified

September 1, 2009

Enrollment Period

1 year

First QC Date

September 2, 2009

Last Update Submit

October 19, 2010

Conditions

Conversion Disorder

Keywords

conversioncytokineinflammation

Study Arms (2)

Conversion disorder

Other: conversion disorder

Healthy control

Other: conversion disorder

Interventions

conversion disorderOTHER

Proinflammatory cytokine levels in conversion disorder

Conversion disorderHealthy control

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

primary care clinic

You may qualify if:

  • Clinical diagnosis of Alzheimer's Disease

You may not qualify if:

  • Autoimmune disease
  • Neurological disease
  • Any organic disorder that could possibly affect proinflammatory cytokines
  • Pregnancy
  • Any drug usage within 2 weeks
  • Any active or passive immunization within 6 months
  • Any other DSM-IV axis I psychiatric disorder
  • Mental retardation
  • Developmental disorder of childhood

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Trakya University Faculty of Medicine; Department of Psychiatry

Edirne, 22030, Turkey (Türkiye)

Location

Related Publications (3)

  • Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 2001 Dec 31;105(3):165-74. doi: 10.1016/s0165-1781(01)00338-9.

    PMID: 11814536BACKGROUND

  • Ziemssen T, Kern S. Psychoneuroimmunology--cross-talk between the immune and nervous systems. J Neurol. 2007 May;254 Suppl 2:II8-11. doi: 10.1007/s00415-007-2003-8.

    PMID: 17503136BACKGROUND

  • Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology. 2005 Nov;30(10):947-52. doi: 10.1016/j.psyneuen.2005.03.011.

    PMID: 15949897BACKGROUND

MeSH Terms

Conditions

Conversion DisorderInflammation

Condition Hierarchy (Ancestors)

Somatoform DisordersMental DisordersPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 2, 2009

First Posted

September 3, 2009

Study Start

September 1, 2009

Primary Completion

September 1, 2010

Study Completion

September 1, 2010

Last Updated

October 20, 2010

Record last verified: 2009-09

Locations

TU(1)